История и перспективы развития метода коронарного стентирования (краткий очерк)

Обложка

Цитировать

Полный текст

Аннотация

Данная статья посвящена истории развития коронарного стентирования, обзору современных технологий и перспективам дальнейшего развития данной методики.

Об авторах

А. И Аналеев

ФГБУ ВПО Институт повышения квалификации ФМБА России

Email: anton-analeev@yandex.ru
ассистент каф. рентгенэндоваскулярных и миниинвазивных методов диагностики и лечения ФГБУ ВПО ИПК 125371, Россия, Москва, Волоколамское ш., д. 91

С. П Семитко

ФГБУ ВПО Институт повышения квалификации ФМБА России; ГБУЗ Городская клиническая больница им. В.В.Вересаева

Email: semitko@mail.ru
д-р мед. наук, проф., зав. каф. рентгенэндоваскулярных и миниинвазивных методов диагностики и лечения ФГБУ ВПО ИПК, ГБУЗ ГКБ им. В.В.Вересаева 125371, Россия, Москва, Волоколамское ш., д. 91; 127644, Россия, Москва, ул. Лобненская, д. 10

Список литературы

  1. Gruntzig A. Transluminal dilatation of coronary - artery stenosis. Lancet 1978; 1: 263.
  2. Garg S, Serruys P.W. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1-42.
  3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835-46.
  4. Chandrasekar B, Tanguay J.F. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555-62.
  5. Clowes A.W, Reidy M.A, Clowes M.M. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208-15.
  6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459-70.
  7. Bennett M.R. In - stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-24.
  8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-6.
  9. De Feyter P.J, De Jaegere P.P, Serruys P.W. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-51.
  10. Serruys P.W, Strauss B.H, Beatt K.J et al. Angiographic follow - up after placement of a selfexpanding coronary - artery stent. N Engl J Med 1991; 324: 13-7.
  11. Serruys P.W, De Jaegere P, Kiemeneij F et al. A comparison of balloon - expandable - stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489-95.
  12. Fischman D.L, Leon M.B, Baim D.S et al. A randomized comparison of coronary - stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496-501.
  13. Hoffmann R, Mintz G.S, Dussaillant G.R et al. Patterns and mechanisms of in - stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247-54.
  14. Chen M.S, John J.M, Chew D.P et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-4.
  15. Morice M.C, Serruys P.W, Sousa J.E et al. A randomized comparison of a sirolimus - eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
  16. Moses J.W, Leon M.B, Popma J.J et al. Sirolimus - eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
  17. Stone G.W, Ellis S.G, Cox D.A et al. A polymer - based, paclitaxel - eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
  18. Poon M, Marx S.O, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-83.
  19. Axel D.I, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45.
  20. Abizaid A. Sirolimus - eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191-201.
  21. Mc Fadden E.P, Stabile E, Regar E et al. Late thrombosis in drug - eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
  22. Nordmann A.J, Briel M, Bucher H.C. Mortality in randomized controlled trials comparing drug - eluting vs. bare metal stents in coronary artery disease: a meta - analysis. Eur Heart J 2006; 27: 2784-814.
  23. Camenzind E, Steg P.G, Wijns W. Stent thrombosis late after implantation of first - generation drug - eluting stents: a cause for concern. Circulation 2007; 115: 1440-55. Discussion 1455.
  24. Laskey W.K, Yancy C.W, Maisel W.H. Thrombosis in coronary drug - eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7-8, 2006. Circulation 2007; 115: 2352-7.
  25. Schomig A, Neumann F.J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary - artery stents. N Engl J Med 1996; 334: 1084-9.
  26. Mehta S.R, Yusuf S, Peters R.J et al. Effects of pretreatment with clopidogrel and aspirin followed by long - term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
  27. Morton A.C, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196-205.
  28. Amin A.P, Spertus J.A, Cohen D.J et al. Use of drug - eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145-52.
  29. Fajadet J, Wijns W, Laarman G.J et al. Randomized, double - blind, multicenter study of the endeavor zotarolimus - eluting phosphorylcholine - encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798-806.
  30. Serruys P.W, Silber S, Garg S et al. Comparison of zotarolimus - eluting and everolimus - eluting coronary stents. N Engl J Med 2010; 363: 136-46.
  31. Stone G.W, Midei M, Newman W et al. Comparison of an everolimus - eluting stent and a paclitaxel - eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-13.
  32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug - eluting and bare - metal stents: evidence from a comprehensive network meta - analysis. Lancet 2012; 379: 1393-402.
  33. Windecker S, Serruys P.W, Wandel S et al. Biolimus - eluting stent with biodegradable polymer versus sirolimus - eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non - inferiority trial. Lancet 2008; 372: 1163-73.
  34. Regar E, Sianos G, Serruys P.W. Stent development and local drug delivery. Br Med Bull 2001; 59: 227-48.
  35. Park K.W, Kang S.H, Velders M.A et al. Safety and efficacy of everolimus - versus sirolimus - eluting stents: a systematic review and meta - analysis of 11 randomized trials. Am Heart J 2013; 165: 241-50 e244.
  36. Greenhalgh J, Hockenhull J, Rao N et al. Drug - eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
  37. Pfisterer M, Brunner-La Rocca H.P, Rickenbacher P et al. Long - term benefit - risk balance of drug - eluting vs. Bare - metal stents in daily practice: does stent diameter matter? Three - year follow - up of BASKET. Eur Heart J 2009; 30: 16-24.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).